Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
On March 30, 2026, Telomir Pharmaceuticals, Inc. disclosed that it had received notice from the Nasdaq Capital Markets confirming its return to compliance with Nasdaq Listing Rule 5620(a), following the successful holding of its 2025 Annual Meeting of Shareholders. The resolution of this matter removes an overhang regarding the company’s listing status, stabilizing its position on the exchange and reducing a source of uncertainty for investors and other stakeholders.
The most recent analyst rating on (TELO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceuticals and life sciences sector. The company focuses on developing therapeutics, though this notice centers on its status as a publicly listed entity rather than detailing specific products or therapeutic areas.
Average Trading Volume: 120,803
Technical Sentiment Signal: Sell
Current Market Cap: $39.19M
Find detailed analytics on TELO stock on TipRanks’ Stock Analysis page.